Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Swedish Orphan Biovitrum AB Sobi
Swedish Orphan Biovitrum AB Sobi
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Ingredients
Therapeutic: efanesoctocog alfa for haemophilia A
Haemophilia A is a rare genetic disorder in which the blood cannot clot properly; this is caused by a lack of factor VIII, one of the proteins involved in the clotting cascade
Recruitment
Sobi appoints Head of Technical Operations
Research & Development
Sobi Orfadin capsules approved in Saudi Arabia
Swedish Orphan Biovitrum's orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1
Estates & Facilities
Sobi opens office in Greece
The company is welcomed by those hoping for innovative therapeutic solutions in Greece
Regulatory
Sobi’s Elocta approved in Switzerland for the treatment of haemophilia A
Elocta is indicated for both on-demand and prophylaxis treatment of people with haemophilia A of all ages
Manufacturing
Sobi signs manufacturing agreements with Pfizer
Sobi is dedicated to developing and delivering innovative therapies for rare diseases
Chief Medical Officer Birgitte Volck to leave Sobi
To join GlaxoSmithKline as Head of R&D Rare Diseases
Subscribe now